Korean J Hematol 2002; 37(3):
Published online September 30, 2002
© The Korean Society of Hematology
동종 골수이식 후 재발한 급성전골수구성백혈병 환자에서 Arsenic Trioxide를 이용한 관해 유도
송해정, 이남수, 김소은, 김찬규, 이규택, 박성규, 원종호, 백승호, 홍대식, 박희숙
순천향대학교 의과대학 내과학교실 종양혈액내과
Remission Induction by Arsenic Trioxide in Patient with Relapsed Acute Promyelocytic Leukemia after Allogeneic Bone Marrow Transplantation
All-trans retinoic acid (ATRA) therapy induces complete remission in acute promyelocytic leukemia (APL) via differentiation ofthe APL cells. Recent clinical trials in China and United states showed that arsenic trioxide (ATO) is an effective and relatively safe drug in thetreatment of APL.
The patients was 29-year-old woman with APL who had been treated heavily with allogeneic bone marrow transplantation (BMT) in 4 years ago and reinduction chemotherapy puls donor lymphocyte infusion (DLI) after relapse in 2 years ago. After diagnosis for relapse, she had been treated with ATRA, but unfortunately failed. She was treated with ATO at the dose of 10 ㎎/day intravenously for 6 weeks. Complete remission was achieved at weeks and the cumulative dose of ATO during induction was 420㎎. She had complete remission without severe adverse effects except mild impairment of liver function and is following up for 6 months.
We report a case o fremission induction by ATO in ATRA refractory APL patient who experienced multiple relapse after allogeneic BMT, chemotherapy and DLI.
Keywords Acute promyelocytic leukemia; Arsenic trioxide;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 2002; 37(3): 218-222
Published online September 30, 2002
Copyright © The Korean Society of Hematology.
동종 골수이식 후 재발한 급성전골수구성백혈병 환자에서 Arsenic Trioxide를 이용한 관해 유도
송해정, 이남수, 김소은, 김찬규, 이규택, 박성규, 원종호, 백승호, 홍대식, 박희숙
순천향대학교 의과대학 내과학교실 종양혈액내과
Remission Induction by Arsenic Trioxide in Patient with Relapsed Acute Promyelocytic Leukemia after Allogeneic Bone Marrow Transplantation
Hae Jeong Song, Nam Su Lee, So Eun Kim, Chan Kyu Kim, Gyu Taeg Lee, Sung Gyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park
Division of Hematology Oncology, Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea
Abstract
All-trans retinoic acid (ATRA) therapy induces complete remission in acute promyelocytic leukemia (APL) via differentiation ofthe APL cells. Recent clinical trials in China and United states showed that arsenic trioxide (ATO) is an effective and relatively safe drug in thetreatment of APL.
The patients was 29-year-old woman with APL who had been treated heavily with allogeneic bone marrow transplantation (BMT) in 4 years ago and reinduction chemotherapy puls donor lymphocyte infusion (DLI) after relapse in 2 years ago. After diagnosis for relapse, she had been treated with ATRA, but unfortunately failed. She was treated with ATO at the dose of 10 ㎎/day intravenously for 6 weeks. Complete remission was achieved at weeks and the cumulative dose of ATO during induction was 420㎎. She had complete remission without severe adverse effects except mild impairment of liver function and is following up for 6 months.
We report a case o fremission induction by ATO in ATRA refractory APL patient who experienced multiple relapse after allogeneic BMT, chemotherapy and DLI.
Keywords: Acute promyelocytic leukemia, Arsenic trioxide,
Previous Article
